HomeBUSINESS
BUSINESS

Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
(May.11.2017)

Takeda Pharmaceutical saw its Japan ethical drug sales fall 6.8% year on year to 504.7 billion yen in the year ended March 2017 due to the divestiture of long-listed products (LLPs), or off-patent brand-name drugs, but its underlining revenue in the country, excluding such one-time factors, rose 5.0% to 481.6 billion yen ...
(LOG IN FOR FULL STORY)

News Calendar